A. V. Rudakova. (2015). COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS. IRBIS LLC.
Chicago Style (17th ed.) CitationA. V. Rudakova. COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS. IRBIS LLC, 2015.
MLA (9th ed.) CitationA. V. Rudakova. COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS. IRBIS LLC, 2015.
Warning: These citations may not always be 100% accurate.